Navigation Links
Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
Date:12/11/2013

ANAHEIM, Calif., Dec. 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about January 24, 2014 to shareholders of record at the close of business on January 17, 2014.

The Company also announced today that it made open market purchases during the fourth quarter of 2013 of approximately 500,000 shares of Questcor common stock through December 10, 2013. The shares were purchased at an average price of $57.21 per share.

Through its repurchase program and its dividend, Questcor has returned approximately $440 million to shareholders since the beginning of 2008, representing approximately 60% of its operating cash flow over that same period.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following approved indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
2. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
3. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
4. Questcor Honored as an "Everyday Hero" by NephCure Foundation
5. Questcor Adds G. Kelly Martin to Board of Directors
6. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
7. Questcor Reports Third Quarter Financial Results
8. Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
9. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
10. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
11. Questcor to Commence Phase 2 Study of Acthar for ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... -- New research provides evidence that an old drug may provide ... released today that will be presented at the American ... Boston , April 22 to 28, 2017. ... the oral drug levodopa has long been considered the gold ... disease progresses, the effects of the medication can partially wear ...
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
Breaking Medicine Technology:
(Date:4/24/2017)... Sacramento, Calif. (PRWEB) , ... April 24, 2017 , ... ... nearly $1.6 million in charitable dental services to 1,961 people during the April 22-23 ... services at no charge to Californians who experience barriers to care, CDA Cares educates ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Veteran Theresa James ... next changed her life forever. , In “Healing Tears,” James depicts every parent’s worst ... of my attorney, I began journaling conversations and situations throughout my divorce,” James said. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP Nutrition®, a company based ... popular products are now available for purchase on StackedNutrition.com, a popular website specializing ... premium natural ingredients in making all of its products. These ingredients come from ...
(Date:4/24/2017)... ... 2017 , ... My T Chai, a South African company that creates a ... on RevNutrition.com, a popular website specializing in sales of nutritional products. , Chai ... and Siam. It spread across Asia and Africa quickly, and today recipes vary from ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
Breaking Medicine News(10 mins):